The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2014 | Impressive results from phase 3 RESONATE trial in CLL
Prof Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the results of the phase 3 RESONATE trial of 391 patients with relapsed or refractory chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL). Prof Hillmen outlines the progression-free and overall survival results which showed the significant benefits of ibrutinib over ofatumumab. He comments on single versus combination therapy with ibrutinib in CLL.
